• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Giltner Richard sold $879,214 worth of shares (3,036 units at $289.60) and exercised 5,000 shares at a strike of $175.43, increasing direct ownership by 11% to 19,384 units (SEC Form 4)

    6/25/25 4:36:23 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UTHR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Giltner Richard

    (Last) (First) (Middle)
    C/O UNITED THERAPEUTICS CORPORATION
    1000 SPRING STREET

    (Street)
    SILVER SPRING MD 20910

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    UNITED THERAPEUTICS Corp [ UTHR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/24/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/24/2025 M 5,000 A $175.43 22,420 D
    Common Stock 06/24/2025 S(1) 3,036 D $289.5962 19,384 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $175.43 06/24/2025 M 5,000 06/26/2016 06/26/2025 Common Stock 5,000 $0.00 0.00 D
    Explanation of Responses:
    1. Exercise of stock options in a cashless sell-to-cover transaction, where a sufficient number of shares was sold to cover the exercise price.
    Remarks:
    /s/ John S. Hess, Jr. under Power of Attorney 06/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $UTHR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $UTHR

    DatePrice TargetRatingAnalyst
    6/2/2025$405.00Overweight
    Cantor Fitzgerald
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    7/11/2024$310.00 → $321.00Overweight → Equal-Weight
    Morgan Stanley
    2/12/2024$213.00 → $215.00Sell → Neutral
    Goldman
    2/5/2024$330.00Outperform
    Leerink Partners
    12/8/2023$309.00Overweight
    Wells Fargo
    12/6/2022$320.00Buy
    UBS
    More analyst ratings

    $UTHR
    SEC Filings

    See more
    • United Therapeutics Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)

      6/27/25 7:30:39 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by United Therapeutics Corporation

      SD - UNITED THERAPEUTICS Corp (0001082554) (Filer)

      5/30/25 4:30:38 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by United Therapeutics Corporation

      SCHEDULE 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      5/12/25 10:44:45 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

      United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mis

      7/16/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

      A phase 1 study of miroliverELAP for the treatment of acute liver failure is currently underway;1 first patient in the study underwent the procedure at Intermountain Medical Center in Murray, Utah Approximately 30% of acute liver failure (ALF) patients die without access to a liver transplant.2 United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and Intermountain Health, one of the nation's top health systems and the largest nonprofit health system in the Intermountain West, today announced the world's first patient treated in a clinical study of a bioengineered external liver assist product called miroliverELAP®. This study is the first human clinical trial

      6/24/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

      Ralinepag has the potential to be the first once-a-day oral prostacyclin agonist for patients with pulmonary arterial hypertension ADVANCE OUTCOMES will continue to accrue clinical worsening events through the end of 2025 and top-line data is expected in the first half of 2026 United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the conclusion of enrollment of the phase 3 ADVANCE OUTCOMES study evaluating the use of an extended-release formulation of ralinepag for the treatment of pulmonary arterial hypertension (PAH). The ADVANCE OUTCOMES study enrolled 728 participants. Clinical worsening events will be accrued through the end of 2025 and top-line

      6/23/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $135.42 and sold $3,303,394 worth of shares (11,000 units at $300.31) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      7/14/25 4:30:45 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $135.42 and sold $3,142,718 worth of shares (11,000 units at $285.70) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      6/27/25 4:39:14 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mesa Nilda sold $187,045 worth of shares (645 units at $289.99), decreasing direct ownership by 12% to 4,883 units (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      6/25/25 4:38:14 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Leadership Updates

    Live Leadership Updates

    See more
    • IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

      WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

      1/27/21 8:00:00 AM ET
      $CLGN
      $UTHR
      $XERS
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

      SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      11/8/24 4:30:29 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by United Therapeutics Corporation

      SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      10/16/24 1:03:48 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

      SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      6/10/24 12:15:17 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on United Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $405.00

      6/2/25 8:55:47 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics downgraded by Wells Fargo

      Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight

      4/25/25 8:31:30 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded United Therapeutics from Underperform to Neutral and set a new price target of $314.00

      4/21/25 8:09:51 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UTHR
    Financials

    Live finance-specific insights

    See more
    • United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

      United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mis

      7/16/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation Reports First Quarter 2025 Financial Results

      United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout

      4/30/25 6:30:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

      United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi

      4/16/25 7:00:00 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care